1. Home
  2. INSM vs ALB Comparison

INSM vs ALB Comparison

Compare INSM & ALB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ALB
  • Stock Information
  • Founded
  • INSM 1988
  • ALB 1994
  • Country
  • INSM United States
  • ALB United States
  • Employees
  • INSM N/A
  • ALB N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ALB Major Chemicals
  • Sector
  • INSM Health Care
  • ALB Industrials
  • Exchange
  • INSM Nasdaq
  • ALB Nasdaq
  • Market Cap
  • INSM 12.5B
  • ALB 11.7B
  • IPO Year
  • INSM 2000
  • ALB 1994
  • Fundamental
  • Price
  • INSM $71.86
  • ALB $107.67
  • Analyst Decision
  • INSM Strong Buy
  • ALB Hold
  • Analyst Count
  • INSM 16
  • ALB 22
  • Target Price
  • INSM $83.64
  • ALB $114.81
  • AVG Volume (30 Days)
  • INSM 1.6M
  • ALB 2.3M
  • Earning Date
  • INSM 10-31-2024
  • ALB 11-06-2024
  • Dividend Yield
  • INSM N/A
  • ALB 1.48%
  • EPS Growth
  • INSM N/A
  • ALB N/A
  • EPS
  • INSM N/A
  • ALB N/A
  • Revenue
  • INSM $342,958,000.00
  • ALB $6,501,978,000.00
  • Revenue This Year
  • INSM $18.96
  • ALB N/A
  • Revenue Next Year
  • INSM $41.96
  • ALB $7.33
  • P/E Ratio
  • INSM N/A
  • ALB N/A
  • Revenue Growth
  • INSM 22.13
  • ALB N/A
  • 52 Week Low
  • INSM $21.92
  • ALB $71.97
  • 52 Week High
  • INSM $80.53
  • ALB $153.54
  • Technical
  • Relative Strength Index (RSI)
  • INSM 51.18
  • ALB 58.21
  • Support Level
  • INSM $64.86
  • ALB $99.58
  • Resistance Level
  • INSM $73.95
  • ALB $110.18
  • Average True Range (ATR)
  • INSM 2.98
  • ALB 4.67
  • MACD
  • INSM 0.26
  • ALB 0.52
  • Stochastic Oscillator
  • INSM 72.73
  • ALB 78.65

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About ALB Albemarle Corporation

Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.

Share on Social Networks: